CD19 and graft versus host disease: Of the 14 patients who died from GVHD, 3 had DLI-related GVHD (2 for relapse prevention and 1 for MRD-positive treatment intervention after the second transplant), and 2 had GVHD following CD19 and/or CD22 CAR-T therapy (MRD-positive post second transplant).